DE69737658T2 - Polyanionische polymere als adjuvantien zur mukosalen immunisierung - Google Patents
Polyanionische polymere als adjuvantien zur mukosalen immunisierung Download PDFInfo
- Publication number
- DE69737658T2 DE69737658T2 DE69737658T DE69737658T DE69737658T2 DE 69737658 T2 DE69737658 T2 DE 69737658T2 DE 69737658 T DE69737658 T DE 69737658T DE 69737658 T DE69737658 T DE 69737658T DE 69737658 T2 DE69737658 T2 DE 69737658T2
- Authority
- DE
- Germany
- Prior art keywords
- adjuvant
- antigen
- paa
- experimental animals
- ndv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000447 polyanionic polymer Polymers 0.000 title claims abstract description 19
- 230000003053 immunization Effects 0.000 title description 68
- 238000002649 immunization Methods 0.000 title description 68
- 239000002671 adjuvant Substances 0.000 claims abstract description 339
- 229960005486 vaccine Drugs 0.000 claims abstract description 162
- 230000006698 induction Effects 0.000 claims abstract description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000016379 mucosal immune response Effects 0.000 claims abstract description 4
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000427 antigen Substances 0.000 claims description 256
- 108091007433 antigens Proteins 0.000 claims description 255
- 102000036639 antigens Human genes 0.000 claims description 255
- 238000002360 preparation method Methods 0.000 claims description 97
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 8
- 125000000129 anionic group Chemical group 0.000 abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- LZSNGCBGVADDSH-UHFFFAOYSA-N (2-ethenylphenyl) hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1C=C LZSNGCBGVADDSH-UHFFFAOYSA-N 0.000 abstract 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 abstract 1
- QNIRRHUUOQAEPB-UHFFFAOYSA-N 2-(prop-2-enoylamino)butane-2-sulfonic acid Chemical compound CCC(C)(S(O)(=O)=O)NC(=O)C=C QNIRRHUUOQAEPB-UHFFFAOYSA-N 0.000 abstract 1
- SQVSEQUIWOQWAH-UHFFFAOYSA-N 2-hydroxy-3-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)OCC(O)CS(O)(=O)=O SQVSEQUIWOQWAH-UHFFFAOYSA-N 0.000 abstract 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 abstract 1
- UYRCWWINMMLRGJ-UHFFFAOYSA-N 3-ethenoxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC=C UYRCWWINMMLRGJ-UHFFFAOYSA-N 0.000 abstract 1
- IRQWEODKXLDORP-UHFFFAOYSA-N 4-ethenylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=C)C=C1 IRQWEODKXLDORP-UHFFFAOYSA-N 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 abstract 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 abstract 1
- VEWLDLAARDMXSB-UHFFFAOYSA-N ethenyl sulfate;hydron Chemical compound OS(=O)(=O)OC=C VEWLDLAARDMXSB-UHFFFAOYSA-N 0.000 abstract 1
- 150000002170 ethers Chemical group 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 150000002334 glycols Chemical group 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- RAGRPVMAKIWULP-UHFFFAOYSA-N n'-ethenylbutanediamide Chemical compound NC(=O)CCC(=O)NC=C RAGRPVMAKIWULP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 303
- 238000009472 formulation Methods 0.000 description 219
- 238000010171 animal model Methods 0.000 description 196
- 210000004027 cell Anatomy 0.000 description 177
- 239000006285 cell suspension Substances 0.000 description 159
- 241000711404 Avian avulavirus 1 Species 0.000 description 150
- 229920002125 Sokalan® Polymers 0.000 description 98
- 210000004072 lung Anatomy 0.000 description 79
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- 239000011550 stock solution Substances 0.000 description 74
- 239000000243 solution Substances 0.000 description 64
- 210000005265 lung cell Anatomy 0.000 description 52
- 210000000952 spleen Anatomy 0.000 description 52
- -1 butyl PAA ester Chemical class 0.000 description 50
- 229920001577 copolymer Polymers 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 40
- 210000004989 spleen cell Anatomy 0.000 description 39
- 238000012360 testing method Methods 0.000 description 37
- 101710160637 Cholera enterotoxin subunit B Proteins 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 229920000642 polymer Polymers 0.000 description 32
- 241000282898 Sus scrofa Species 0.000 description 31
- 230000036039 immunity Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000000034 method Methods 0.000 description 25
- 239000000178 monomer Substances 0.000 description 25
- 239000008055 phosphate buffer solution Substances 0.000 description 25
- 239000002502 liposome Substances 0.000 description 22
- 239000008363 phosphate buffer Substances 0.000 description 22
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 20
- 229940032094 squalane Drugs 0.000 description 20
- 229910021642 ultra pure water Inorganic materials 0.000 description 19
- 239000012498 ultrapure water Substances 0.000 description 19
- 239000000872 buffer Substances 0.000 description 17
- 239000004584 polyacrylic acid Substances 0.000 description 17
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 16
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 16
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 14
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 13
- 229960002796 polystyrene sulfonate Drugs 0.000 description 13
- 239000011970 polystyrene sulfonate Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 230000003292 diminished effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 229960000633 dextran sulfate Drugs 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 7
- 208000037797 influenza A Diseases 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229960000380 propiolactone Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- XESUCHPMWXMNRV-UHFFFAOYSA-M sodium;2-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1C=C XESUCHPMWXMNRV-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical group [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9622159 | 1996-10-24 | ||
| GBGB9622159.3A GB9622159D0 (en) | 1996-10-24 | 1996-10-24 | Polyanionic polymers as adjuvants for mucosal immunization |
| PCT/EP1997/005861 WO1998017310A2 (en) | 1996-10-24 | 1997-10-23 | Polyanionic polymers as adjuvants for mucosal immunization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69737658D1 DE69737658D1 (de) | 2007-06-06 |
| DE69737658T2 true DE69737658T2 (de) | 2008-01-31 |
Family
ID=10801896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69737658T Expired - Lifetime DE69737658T2 (de) | 1996-10-24 | 1997-10-23 | Polyanionische polymere als adjuvantien zur mukosalen immunisierung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6610310B2 (https=) |
| EP (1) | EP0934077B1 (https=) |
| JP (1) | JP4344014B2 (https=) |
| AT (1) | ATE360440T1 (https=) |
| AU (1) | AU717349B2 (https=) |
| BR (1) | BR9712436A (https=) |
| CA (1) | CA2269780C (https=) |
| DE (1) | DE69737658T2 (https=) |
| ES (1) | ES2285741T3 (https=) |
| GB (1) | GB9622159D0 (https=) |
| WO (1) | WO1998017310A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
| US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
| US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| AU2003288058A1 (en) * | 2002-11-14 | 2004-06-03 | Novartis Ag | Antibody- or neutrophil-mediated ozone generation |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| JP4860109B2 (ja) * | 2003-12-26 | 2012-01-25 | バイオリーダース・コーポレイション | ポリガンマグルタミン酸を含む免疫増強用組成物 |
| DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| US20090017064A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| FR2922767B1 (fr) * | 2007-10-24 | 2009-12-18 | Seppic Sa | Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant. |
| UA98812C2 (ru) | 2007-11-06 | 2012-06-25 | Вайет Ллк | Авирулентная активированная живая вакцина mycoplasma hyopneumoniae |
| EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| TW201010719A (en) * | 2008-08-19 | 2010-03-16 | Wyeth Corp | Immunological composition |
| GB0907989D0 (en) | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| SG10201406432RA (en) | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| US20110110980A1 (en) | 2009-09-02 | 2011-05-12 | Wyeth Llc | Heterlogous prime-boost immunization regimen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| WO2012017288A2 (en) | 2010-08-04 | 2012-02-09 | Carlo Ghisalberti | Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair |
| CN107913396B (zh) | 2010-08-23 | 2022-03-08 | 惠氏有限责任公司 | 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂 |
| AU2011300409B2 (en) | 2010-09-10 | 2015-03-26 | Wyeth Llc | Non-lipidated variants of Neisseria meningitidis ORF2086 antigens |
| EP2654784B1 (en) | 2010-12-22 | 2016-12-07 | Wyeth LLC | Stable immunogenic compositions of staphylococcus aureus antigens |
| DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| DE102010056566A1 (de) * | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Kontinuierliches Verfahren zur Veresterung Säuregruppen tragender Polymere |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| JP6502262B2 (ja) | 2012-12-20 | 2019-04-17 | ファイザー・インク | 糖複合化方法 |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| EP3049106A1 (en) | 2013-09-25 | 2016-08-03 | Zoetis Services LLC | Pcv2b divergent vaccine composition and methods of use |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| MY182282A (en) | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| BR112018076015A8 (pt) * | 2016-06-17 | 2022-06-28 | Sanofi Pasteur | Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US11433139B2 (en) | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| CN109134724A (zh) * | 2018-07-24 | 2019-01-04 | 石家庄哈顿生物技术有限公司 | 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法 |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| KR20230056727A (ko) | 2020-08-26 | 2023-04-27 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4567042A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| ES2052685T3 (es) * | 1987-03-17 | 1994-07-16 | Akzo Nv | Metodo para producir un adyuvante libre. |
| US5242686A (en) * | 1990-11-07 | 1993-09-07 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
| EP0532833A1 (en) * | 1991-05-28 | 1993-03-24 | Miles Inc. | Vaccine for equine rhinopneumonitis |
| BE1008977A5 (fr) * | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
-
1996
- 1996-10-24 GB GBGB9622159.3A patent/GB9622159D0/en active Pending
-
1997
- 1997-10-23 US US09/297,214 patent/US6610310B2/en not_active Expired - Lifetime
- 1997-10-23 WO PCT/EP1997/005861 patent/WO1998017310A2/en not_active Ceased
- 1997-10-23 AT AT97950021T patent/ATE360440T1/de not_active IP Right Cessation
- 1997-10-23 EP EP97950021A patent/EP0934077B1/en not_active Expired - Lifetime
- 1997-10-23 CA CA002269780A patent/CA2269780C/en not_active Expired - Lifetime
- 1997-10-23 ES ES97950021T patent/ES2285741T3/es not_active Expired - Lifetime
- 1997-10-23 JP JP51897598A patent/JP4344014B2/ja not_active Expired - Lifetime
- 1997-10-23 BR BR9712436-2A patent/BR9712436A/pt not_active Application Discontinuation
- 1997-10-23 DE DE69737658T patent/DE69737658T2/de not_active Expired - Lifetime
- 1997-10-23 AU AU53133/98A patent/AU717349B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001507336A (ja) | 2001-06-05 |
| WO1998017310A2 (en) | 1998-04-30 |
| DE69737658D1 (de) | 2007-06-06 |
| BR9712436A (pt) | 2000-10-24 |
| CA2269780A1 (en) | 1998-04-30 |
| EP0934077A2 (en) | 1999-08-11 |
| EP0934077B1 (en) | 2007-04-25 |
| JP4344014B2 (ja) | 2009-10-14 |
| ES2285741T3 (es) | 2007-11-16 |
| AU717349B2 (en) | 2000-03-23 |
| WO1998017310A3 (en) | 1998-06-18 |
| CA2269780C (en) | 2008-12-02 |
| US20030021793A1 (en) | 2003-01-30 |
| US6610310B2 (en) | 2003-08-26 |
| ATE360440T1 (de) | 2007-05-15 |
| GB9622159D0 (en) | 1996-12-18 |
| AU5313398A (en) | 1998-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69737658T2 (de) | Polyanionische polymere als adjuvantien zur mukosalen immunisierung | |
| DE69530227T2 (de) | Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln | |
| DE69519670T2 (de) | Mikropartikel mit abgabesystem | |
| DE69428795T2 (de) | Phosphazene und polyelektrolyte als immunadjuvantien | |
| DE69534686T2 (de) | Antivirale dendrimere | |
| DE68926828T2 (de) | Verfahren zur Potenzierung einer Immunreaktion sowie die dazugehörigen Mittel | |
| DE69010574T2 (de) | Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält. | |
| DE60112073T2 (de) | Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren | |
| DE69934179T2 (de) | Zusammensetzung enthaltend ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure zur Verwendung in der Immunisierung | |
| DE69826842T2 (de) | Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a | |
| DE69427126T2 (de) | Hydrophobe polymer mikropartikel | |
| DE69620182T2 (de) | Polymere lamellare substratpartikel zur arzneistoffverabreichung | |
| DE69329030T2 (de) | Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten | |
| DE69526856T2 (de) | Nukleinsäure enthaltender impstoff | |
| DE69225710T3 (de) | Anregung von antworten zytotoxischer t-lymphozyten | |
| DE69834921T2 (de) | Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält | |
| DE3750176T2 (de) | Impfstoff und verfahren zur herstellung. | |
| DE69131709T2 (de) | Liposomen enthaltende impfstoffzusammensetzungen | |
| DE69427824T2 (de) | Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung | |
| EP0734725B1 (de) | Adjuvans auf der Basis kolloidaler Eisenverbindungen | |
| Dalsgaard | Adjuvants | |
| DE69822542T2 (de) | Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff. | |
| DE60004334T2 (de) | Impfstoffzusammensetzung auf basis von partikeln | |
| DE60031243T2 (de) | Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant | |
| DE69922804T2 (de) | Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: PFIZER AG, ZUERICH, CH |